792 reports of this reaction
4.7% of all PYRIDOSTIGMINE BROMIDE reports
#1 most reported adverse reaction
MYASTHENIA GRAVIS is the #1 most commonly reported adverse reaction for PYRIDOSTIGMINE BROMIDE. There are 792 FDA adverse event reports linking PYRIDOSTIGMINE BROMIDE to MYASTHENIA GRAVIS. This represents approximately 4.7% of all 16,739 adverse event reports for this drug.
Patients taking PYRIDOSTIGMINE BROMIDE who experience myasthenia gravis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MYASTHENIA GRAVIS is moderately reported among PYRIDOSTIGMINE BROMIDE users, representing a notable but not dominant share of adverse events.
In addition to myasthenia gravis, the following adverse reactions have been reported for PYRIDOSTIGMINE BROMIDE:
The following drugs have also been linked to myasthenia gravis in FDA adverse event reports:
MYASTHENIA GRAVIS has been reported as an adverse event in 792 FDA reports for PYRIDOSTIGMINE BROMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MYASTHENIA GRAVIS accounts for approximately 4.7% of all adverse event reports for PYRIDOSTIGMINE BROMIDE, making it one of the most commonly reported side effect.
If you experience myasthenia gravis while taking PYRIDOSTIGMINE BROMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.